




Searching News Database: radiation dermatitis
HSMN NewsFeed - 19 Apr 2019
CIVCO Radiotherapy Presents Proton Head & Neck Immobilization Solution at ESTRO 38
CIVCO Radiotherapy Presents Proton Head & Neck Immobilization Solution at ESTRO 38
HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
HSMN NewsFeed - 1 Dec 2016
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
HSMN NewsFeed - 27 Jul 2009
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram(R)
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram(R)
HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
HSMN NewsFeed - 19 Nov 2007
Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(R)
Ceragenix and Dr. Reddy's Enter Into Distribution and Supply Agreement for EpiCeram(R)
HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
HSMN NewsFeed - 15 Jun 2007
Former President and CEO of Biomira Alex McPherson Joins Carrington Board of Directors
Former President and CEO of Biomira Alex McPherson Joins Carrington Board of Directors
HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
HSMN NewsFeed - 24 Apr 2007
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
HSMN NewsFeed - 1 Nov 2006
Carrington's DelSite Subsidiary Presents Data on Needle-Free Vaccine Technology
Carrington's DelSite Subsidiary Presents Data on Needle-Free Vaccine Technology
Additional items found! 20

Members Archive contains
20 additional stories matching:
radiation dermatitis
(Password required)
radiation dermatitis
(Password required)